Moguntinones - New selective inhibitors for the treatment of human colorectal cancer

Molecular Cancer Therapeutics

Volumn 13, Issue 6, 2014, Pages 1399-1409

  Maderer, Annett ^a   Plutizki, Stanislav ^a   Kramb, Jan Peter ^a   Göpfert, Katrin ^a   Linnig, Monika ^a   Khillimberger, Katrin ^a   Ganser, Christopher ^a   Lauermann, Eva ^a   Dannhardt, Gerd ^a   Galle, Peter R ^a   Moehler, Markus ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; FLUOROURACIL; IRINOTECAN; MALEIMIDE DERIVATIVE; MAMMALIAN TARGET OF RAPAMYCIN; MOG 13; MOG 19; MOGUNTINONE DERIVATIVE; OXALIPLATIN; SUNITINIB; TOPOTECAN; UNCLASSIFIED DRUG; VANDETANIB; DNA TOPOISOMERASE INHIBITOR; INDOLE DERIVATIVE; MOGUNTINONE 19; MTOR PROTEIN, HUMAN; PROTEIN KINASE B; TARGET OF RAPAMYCIN KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; APOPTOSIS ASSAY; ARTICLE; CANCER CELL LINE; COLORECTAL CANCER; CONTROLLED STUDY; DRUG MECHANISM; DRUG SELECTIVITY; FEMALE; HUMAN; HUMAN CELL; IC 50; MOUSE; NONHUMAN; ONCOGENE K RAS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR VOLUME; WESTERN BLOTTING; ANIMAL; CACO 2 CELL LINE; COLORECTAL NEOPLASMS; DRUG EFFECTS; DRUG SCREENING; GENETICS; HT 29 CELL LINE; METABOLISM; PATHOLOGY;

ANIMALS; APOPTOSIS; CACO-2 CELLS; COLORECTAL NEOPLASMS; HT29 CELLS; HUMANS; INDOLES; MALEIMIDES; MICE; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TOPOISOMERASE I INHIBITORS; TOR SERINE-THREONINE KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84902664242     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0224     Document Type: Article

References (47)

1. Linkous AG, Yazlovitskaya EM. Novel therapeutic approaches for targeting tumor angiogenesis. Anticancer Res 2012;32:1-12.
2. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of antitumour activity. Nat Rev Cancer 2008;8:579-91.
3. Takahashi Y, Nishioka K. Therapeutic approaches targeting tumor vasculature in gastrointestinal cancers. Front Biosci (Elite Ed) 2011; 3:541-8.
4. Ganser C, Lauermann E, Maderer A, Stauder T, Kramb JP, Plutizki S, et al. Novel 3-Azaindolyl-4-arylmaleimides exhibiting potent antiangiogenic efficacy, protein kinase inhibition, and antiproliferative activity. J Med Chem 2012;55:9531-40.
5. Peifer C, Krasowski A, Hammerle N, Kohlbacher O, Dannhardt G, Totzke F, et al. Profile and molecular modeling of 3-(indole-3-yl)-4-(3,4,5- trimethoxyphenyl)-1 H-pyrrole-2,5-dione (1) as a highly selective VEGF-R2/3 inhibitor. J Med Chem 2006;49:7549-53. (Pubitemid 44913415)
6. Peifer C, Stoiber T, Unger E, Totzke F, Schachtele C, Marme D, et al. Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem 2006;49:1271-81. (Pubitemid 43273496)
7. Heidel FH, Mack TS, Razumovskaya E, Blum MC, Lipka DB, Ballaschk A, et al. 3,4-Diarylmaleimides-a novel class of kinase inhibitors-effectively induce apoptosis in FLT3-ITD-dependent cells. Ann Hematol 2012;91:331-44.
8. Manoukian AS, Woodgett JR. Role of glycogen synthase kinase-3 in cancer: regulation by Wnts and other signaling pathways. Adv Cancer Res 2002;84:203-29. (Pubitemid 34188198)
9. Jope RS, Johnson GV. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 2004;29:95-102. (Pubitemid 38186580)
10. Mishra R. Glycogen synthase kinase 3 beta: can it be a target for oral cancer. Mol Cancer 2010;9:144.
11. Phukan S, Babu VS, Kannoji A, Hariharan R, Balaji VN. GSK3beta: role in therapeutic landscape and development of modulators. Br J Pharmacol 2010;160:1-19.
12. Spagnoli GC, Kloth J, Terracciano L, Trutmann M, Chklovskaia E, Remmel E, et al. FLT3 ligand gene expression and protein production in human colorectal cancer cell lines and clinical tumor specimens. Int J Cancer 2000;86:238-43. (Pubitemid 30180819)
13. Ibrahim N, Yu Y, Walsh WR, Yang JL. Molecular targeted therapies for cancer: sorafenib mono-therapy and its combination with other therapies (review). Oncol Rep 2012;27:1303-11.
14. Strumberg D, Schultheis B. Regorafenib for cancer. Expert Opin Investig Drugs 2012;21:879-89.
15. Waddell T, Cunningham D. Evaluation of regorafenib in colorectal cancer and GIST. Lancet 2013;381:273-5.
16. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013;381:303-12.
17. Kohne CH, Lenz HJ. Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer. Oncologist 2009;14:478-88.
18. Lynch TJ Jr, Kim ES, Eaby B, Garey J, West DP, Lacouture ME. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 2007;12:610-21. (Pubitemid 350012125)
19. Bennouna J, Sastre J, Arnold D, Osterlund P, Greil R, Van Cutsem E, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 2013;14:29-37.
20. Chu E. An update on the current and emerging targeted agents in metastatic colorectal cancer. Clin Colorectal Cancer 2012;11:1-13.
21. Lyros O, Mueller A, Heidel F, Schimanski CC, Gockel I, Galle PR, et al. Analysis of anti-proliferative and chemosensitizing effects of sunitinib on human esophagogastric cancer cells: synergistic interaction with vandetanib via inhibition of multi-receptor tyrosine kinase pathways. Int J Cancer 2010;127:1197-208.
22. Mueller A, Bachmann E, Linnig M, Khillimberger K, Schimanski CC, Galle PR, et al. Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines. Cancer Chemother Pharmacol 2012; 69:1601-15.
23. United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR). Guidelines for the Welfare of Animals in Experimental Neoplasia (Second Edition). Br J Cancer 1998;77:1-10.
24. Moehler M, Frings C, Mueller A, Gockel I, Schimanski CC, Biesterfeld S, et al. VEGF-D expression correlates with colorectal cancer aggressiveness and is downregulated by cetuximab. World J Gastroenterol 2008;14:4156-67.
25. Kroger C, Vijayaraj P, Reuter U, Windoffer R, Simmons D, Heukamp L, et al. Placental vasculogenesis is regulated by keratin-mediated hyperoxia in murine decidual tissues. Am J Pathol 2011;178:1578-90.
26. Lievre A, Blons H, Laurent-Puig P. Oncogenic mutations as predictive factors in colorectal cancer. Oncogene 2010;29:3033-43.
27. MaCX, Cai S, Li S, Ryan CE, Guo Z, Schaiff WT, et al. Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models. J Clin Invest 2012;122:1541-52.
28. Fu Y, Zheng S, An N, Athanasopoulos T, Popplewell L, Liang A, et al. beta-catenin as a potential key target for tumor suppression. Int J Cancer 2011;129:1541-51.
29. Klamer G, Song E, Ko KH, O'Brien TA, Dolnikov A. Using small molecule GSK3beta inhibitors to treat inflammation. Curr Med Chem 2010;17:2873-81.
30. Takahashi-Yanaga F, Sasaguri T. GSK-3beta regulates cyclin D1 expression: a new target for chemotherapy. Cell Signal 2008;20:581-9. (Pubitemid 351241128)
31. Ong CS, Zhou J, Ong CN, Shen HM. Luteolin induces G1 arrest in human nasopharyngeal carcinoma cells via the Akt-GSK-3beta-Cyclin D1 pathway. Cancer Lett 2010;298:167-75.
32. Fei HR, Cui LY, Zhang ZR, Zhao Y, Wang FZ. Caudatin inhibits carcinomic human alveolar basal epithelial cell growth and angiogenesis through modulating GSK3beta/beta-catenin pathway. J Cell Biochem 2012;113:3403-10.
33. Wang CY, Tsai AC, Peng CY, Chang YL, Lee KH, Teng CM, et al. Dehydrocostuslactone suppresses angiogenesis in vitro and in vivo through inhibition of Akt/GSK-3beta and mTOR signaling pathways. PLoS One 2012;7:e31195.
34. Zhou W, Wang L, Gou SM, Wang TL, Zhang M, Liu T, et al. ShRNA silencing glycogen synthase kinase-3 beta inhibits tumor growth and angiogenesis in pancreatic cancer. Cancer Lett 2012;316:178-86.
35. Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, Schutz G, et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 2010;129:245-55.
36. Aprile G, Macerelli M, Giuliani F. Regorafenib for gastrointestinal malignancies: from preclinical data to clinical results of a novel multi-target inhibitor. BioDrugs 2013;27:213-24.
37. FDA approves regorafenib (Stivarga) for metastatic colorectal cancer. Oncology (Williston Park) 2012;26:896.
38. Abou-Elkacem L, Arns S, Brix G, Gremse F, Zopf D, Kiessling F, et al. Regorafenib inhibits growth, angiogenesis, and metastasis in a highly aggressive, orthotopic colon cancer model. Mol Cancer Ther 2013;12:1322-31.
39. Kollmar O, Rupertus K, Scheuer C, Nickels RM, Haberl GC, Tilton B, et al. CXCR4 and CXCR7 regulate angiogenesis and CT26.WT tumor growth independent from SDF-1. Int J Cancer 2010;126:1302-15.
40. Lin CW, Liao MY, Lin WW, Wang YP, Lu TY, Wu HC. Epithelial cell adhesion molecule regulates tumor initiation and tumorigenesis via activating reprogramming factors and epithelial-mesenchymal transition gene expression in colon cancer. J Biol Chem 2012;287:39449-59.
41. Pencreach E, Guerin E, Nicolet C, Lelong-Rebel I, Voegeli AC, Oudet P, et al. Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/ hypoxia-inducible factor-1alpha axis. Clin Cancer Res 2009; 15:1297-307.
42. Liu D, Sun J, Zhu J, Zhou H, Zhang Y. The expression and clinical significance of β-catenin and colorectal cancer stem cells marker EpCAMhigh/CD44+ in colorectal cancer. Chin-Ger J Clin Oncol 2013;12:581.
43. Yamashita T, Budhu A, Forgues M, Wang XW. Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma. Cancer Res 2007;67:10831-9. (Pubitemid 350145912)
44. Lippert JW III. Vascular disrupting agents. Bioorg Med Chem 2007; 15:605-15.
45. Hori K. Starvation tactics for solid tumors: tumor blood flow interruption via a combretastatin derivative (Cderiv), and its microcirculation mechanism. Cancer Metastasis Rev 2011;31:109-22.
46. Hori K, Saito S, Kubota K. A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs. Br J Cancer 2002;86:1604-14. (Pubitemid 34628115)
47. Hori K, Saito S, Nihei Y, Suzuki M, Sato Y. Antitumor effects due to irreversible stoppage of tumor tissue blood flow: evaluation of a novel combretastatin A-4 derivative, AC7700. Jpn J Cancer Res 1999;90:1026-38. (Pubitemid 29500444)